U.S. markets open in 3 hours 7 minutes

iShares Public Limited Company - iShares MSCI EM UCITS ETF USD (Dist) (IREMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
52.890.00 (0.00%)
At close: 9:55AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close52.89
Open52.89
BidN/A x N/A
AskN/A x N/A
Day's Range52.89 - 52.89
52 Week Range30.07 - 54.82
Volume96
Avg. Volume225
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
      GlobeNewswire

      Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

      New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with obeticholic acid (OCA) In a real-world study of patients with PBC, Ocaliva® reduced alkaline phosphatase and bilirubin after 1 and 2 years of treatment across patient subgroups NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused